Personal information

Websites & social links

Personal website

Other IDs

Loop profile: 2097584
Scopus Author ID: 57959797000

Keywords

Receptore Tyrosine Kinase, FGFR, SHP2, TLR

Countries

China

Biography

RTKs play critical roles in signal transduction pathways that mediate cell proliferation, differentiation, migration and metabolism, both in organismal development and in homeostasis. My laboratory is focus on the structural basis by which the fibroblast growth factor receptors (FGFR) are activated upon ligand binding. Based on the structure of RTKs, we have been designing and investigating novel RTK small-molecule kinase inhibitors/degraders for the treatment of cancers and inflammatory diseases. In addition, we are interested in the identification of antagonist of the RTK downstream signaling proteins such as SHP2.

Activities

Collapse all

Employment (1)

Hangzhou Medical College: Hangzhou, Zhejiang Province, CN

2021-01-01 to present | Professor (School of Pharmacy)
Employment
Source: Self-asserted source
Lingfeng Chen

Education and qualifications (3)

Nanjing University of Science and Technology: Nanjing, Jiangsu, CN

2016-09-01 to 2020-10-01 | PHD (Chemical Engineering)
Education
Source: Self-asserted source
Lingfeng Chen

New York University: New York, NY, US

2018-04-01 to 2020-05-01 | Visitor (School of Medicine)
Qualification
Source: Self-asserted source
Lingfeng Chen

Wenzhou Medical University: Wenzhou, Zhejiang, CN

2013-09-01 to 2016-06-01 | Master (Pharmaceutical Sciences)
Education
Source: Self-asserted source
Lingfeng Chen

Professional activities (1)

Faculty Opinions: London, GB

2019-10-25 to present | Associate Faculty Member
Invited position
Source: check_circle
Faculty Opinions

Works (17)

FGF-based drug discovery: advances and challenges

Nature Reviews Drug Discovery
2025-01-28 | Journal article
DOI: 10.1038/s41573-024-01125-w
Contributors: Gaozhi Chen; Lingfeng Chen; Xiaokun Li; Moosa Mohammadi
Source: check_circle
Crossref

Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects

Journal of Medicinal Chemistry
2025-01-23 | Journal article
DOI: 10.1021/acs.jmedchem.4c01322
Contributors: Yaoxiang Lin; Lulu Zheng; Ying Xu; Xinyan Wang; Jie Li; Lei Zheng; Guang Liang; Lingfeng Chen
Source: check_circle
Crossref

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases

Journal of Medicinal Chemistry
2024-05-23 | Journal article
DOI: 10.1021/acs.jmedchem.4c00181
Contributors: Lingfeng Chen; Ruixiang Luo; Lin Ma; Ying Xu; Jiaqi Cao; Zheng Jiang; Shiyan Chen; Xiaohao Huang; Mingwan Zhang; Lei Zheng et al.
Source: check_circle
Crossref

Base-Promoted Synthesis of Isoquinolines through a Tandem Reaction of 2-Methyl-arylaldehydes and Nitriles

The Journal of Organic Chemistry
2024-05-17 | Journal article
DOI: 10.1021/acs.joc.4c00123
Contributors: Sujuan Shuai; Jianyou Mao; Fan Zhou; Qifeng Yan; Lingfeng Chen; Jie Li; Patrick J. Walsh; Guang Liang
Source: check_circle
Crossref

Structural basis for FGF hormone signalling

Nature
2023-06-22 | Journal article
DOI: 10.1038/s41586-023-06155-9
Contributors: Lingfeng Chen; Lili Fu; Jingchuan Sun; Zhiqiang Huang; Mingzhen Fang; Allen Zinkle; Xin Liu; Junliang Lu; Zixiang Pan; Yang Wang et al.
Source: check_circle
Crossref

Base-Promoted Tandem Synthesis of 3,4-Dihydroisoquinolones

Organic Letters
2022 | Journal article
DOI: 10.1021/acs.orglett.2c03167
EID:

2-s2.0-85141562145

Part of ISSN: 15237052 15237060
Contributors: Li, J.; Wang, H.; Jin, H.; Xiang, Z.; Chen, L.; Walsh, P.J.; Liang, G.
Source: Self-asserted source
Lingfeng Chen via Scopus - Elsevier

Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.

Journal of experimental & clinical cancer research : CR
2021-11-03 | Journal article
DOI: 10.1186/s13046-021-02156-6
PMID: 34732230
PMC: PMC8564965
Contributors: Chen L; Zhang Y; Yin L; Cai B; Huang P; Li X; Given Names Deactivated Family Name Deactivated
Source: Self-asserted source
Lingfeng Chen

Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling.

Journal of medicinal chemistry
2020-09-29 | Journal article
DOI: 10.1021/acs.jmedchem.0c00884
PMID: 32931267
Contributors: Chen L; Zheng L; Chen P; Given Names Deactivated Family Name Deactivated
Source: Self-asserted source
Lingfeng Chen

Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation

Nature Chemical Biology
2020-03-20 | Journal article
DOI: 10.1038/s41589-019-0455-7
Contributors: Lingfeng Chen; William M. Marsiglia; Huaibin Chen; Joseph Katigbak; Hediye Erdjument-Bromage; David J. Kemble; Lili Fu; Jinghong Ma; Gongqin Sun; Yingkai Zhang et al.
Source: check_circle
Crossref

Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury

Journal of Medicinal Chemistry
2019-06-13 | Journal article
DOI: 10.1021/acs.jmedchem.9b00316
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Lingfeng Chen

Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury

European Journal of Medicinal Chemistry
2019-01 | Journal article
DOI: 10.1016/j.ejmech.2018.09.068
Part of ISSN: 0223-5234
Source: Self-asserted source
Lingfeng Chen

Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseases

Drug Discovery Today
2018-06 | Journal article
DOI: 10.1016/j.drudis.2018.01.015
Part of ISSN: 1359-6446
Source: Self-asserted source
Lingfeng Chen

Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury

European Journal of Medicinal Chemistry
2018-01 | Journal article
DOI: 10.1016/j.ejmech.2017.11.066
Part of ISSN: 0223-5234
Source: Self-asserted source
Lingfeng Chen
grade
Preferred source (of 2)‎

Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC

European Journal of Medicinal Chemistry
2017-11 | Journal article
DOI: 10.1016/j.ejmech.2017.08.061
Contributors: Lingfeng Chen; Weitao Fu; Chen Feng; Rong Qu; Linjiang Tong; Lulu Zheng; Bo Fang; Yinda Qiu; Jie Hu; Yuepiao Cai et al.
Source: check_circle
Crossref

Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer

Journal of Medicinal Chemistry
2017-11-14 | Journal article
Source: Self-asserted source
Lingfeng Chen

Cover Picture: Design, Synthesis, and Structure–Activity Relationship Analysis of Thiazolo[3,2‐a]pyrimidine Derivatives with Anti‐inflammatory Activity in Acute Lung Injury (ChemMedChem 13/2017)

ChemMedChem
2017-07-06 | Journal article
DOI: 10.1002/cmdc.201700367
Contributors: Lingfeng Chen; Yiyi Jin; Weitao Fu; Siyang Xiao; Chen Feng; Bo Fang; Yugui Gu; Chenglong Li; Yunjie Zhao; Zhiguo Liu et al.
Source: check_circle
Crossref

Design, Synthesis, and Structure–Activity Relationship Analysis of Thiazolo[3,2‐a]pyrimidine Derivatives with Anti‐inflammatory Activity in Acute Lung Injury

ChemMedChem
2017-07-06 | Journal article
DOI: 10.1002/cmdc.201700175
Contributors: Lingfeng Chen; Yiyi Jin; Weitao Fu; Siyang Xiao; Chen Feng; Bo Fang; Yugui Gu; Chenglong Li; Yunjie Zhao; Zhiguo Liu et al.
Source: check_circle
Crossref

Peer review (13 reviews for 5 publications/grants)

Review activity for European journal of medicinal chemistry. (8)
Review activity for Faculty Opinions (1)
Review activity for Heliyon. (1)
Review activity for Journal of medicinal chemistry. (2)
Review activity for Signal transduction and targeted therapy. (1)
How many people are using ORCID?